Newly published results from a literature review-based study suggest that primary postpartum hemorrhage (PPH) is a persistent clinical challenge in patients with type 3 von Willebrand disease (VWD), even in those who received their diagnosis before…
NEW YORK (January 17, 2020) – The Board of Directors of the National Hemophilia Foundation (NHF) today announced that Dr. Leonard A. Valentino will be the foundation’s next Chief Executive Officer. Dr. Valentino…
Washington, D.C.—January 15, 2020— Patient and health advocacy groups representing millions of Americans with pre-existing conditions will file an amicus curiae or friend of the court brief today urging the U.S. Supreme Court to…
Findings from a recent study published in the Journal of Pediatric Hematology/Oncology showed that teens with hemophilia scored lower on self esteem measures when compared to a control group. The study was conducted at the Dr Behcet Uz Children’s…
An important new educational activity has launched for healthcare providers who practice in an emergency department setting. “Evaluation and Management of Hemophilia in the Emergency Department” was developed through a partnership between Medscape…
BioMarin recently announced updates on their ongoing clinical trial program for their investigational gene therapy valoctocogene roxaparvovec, which was developed for the treatment of adults with severe hemophilia A. The therapy utilizes adeno-…
Sangamo Therapeutics has handed over development of hemophilia A gene therapy candidate SB-525 to Pfizer. Up to this point, the investigational therapy had been developed by Sangamo, in collaboration with Pfizer.
SB-525, which is now advancing to…
The National Hemophilia Foundation (NHF) is very pleased to announce the 2020 awardees of the Nursing and Social Work Fellowships.
The recipient of the Nursing Excellence Fellowship is Amanda Greene, MSN, BSN, RN. Amanda is…